Table 3.

Association between IL10 haplotypes and risk of total, lower-, and higher-grade prostate cancer in the finasteride arm of the PCPT

IL10 haplotype							Frequencies		OR (95% CI)	P
rs3024498	rs3024496	rs3024509	rs1554286	rs3021094	rs1800894	rs1800890	Case	Control
Total prostate cancer
A	T	T	C	A	G	T	0.30	0.31	1.00 (ref)
A	C	C	C	A	A	T	0.02	0.04	0.66 (0.36–1.20)
A	C	C	C	A	G	T	0.03	0.03	0.77 (0.43–1.39)
A	C	T	C	A	G	A	0.15	0.17	0.92 (0.68–1.24)
A	T	T	C	C	G	T	0.03	0.01	2.11 (0.97–4.63)
A	T	T	T	A	G	T	0.12	0.10	1.18 (0.84–1.67)
A	T	T	T	C	G	T	0.08	0.07	1.13 (0.76–1.70)
G	C	T	C	A	G	A	0.24	0.24	1.02 (0.78–1.34)
G	C	T	C	A	G	T	0.04	0.03	1.34 (0.74–2.44)
All rare haplotypes combined							0.21	0.20	4.00 (0.30–53.5)
									Score test	0.2
Lower-grade prostate cancer (Gleason 2–6)
A	T	T	C	A	G	T	0.29	0.31	1.00 (ref)
A	C	C	C	A	A	T	0.02	0.04	0.67 (0.34–1.34)
A	C	C	C	A	G	T	0.03	0.03	0.99 (0.52–1.87)
A	C	T	C	A	G	A	0.15	0.17	0.91 (0.65–1.29)
A	T	T	C	C	G	T	0.03	0.01	2.39 (1.03–5.56)
A	T	T	T	A	G	T	0.11	0.10	1.12 (0.75–1.67)
A	T	T	T	C	G	T	0.08	0.07	1.19 (0.75–1.89)
G	C	T	C	A	G	A	0.25	0.24	1.09 (0.80–1.48)
G	C	T	C	A	G	T	0.04	0.03	1.27 (0.65–2.50)
All rare haplotypes combined							0.21	0.19	–
									Score test	0.4
Higher-grade prostate cancer (Gleason 7–10)
A	T	T	C	A	G	T	0.34	0.31	1.00 (ref)
A	C	C	C	A	A	T	0.02	0.04	0.67 (0.28–1.57)
A	T	T	T	C	G	T	0.07	0.07	1.04 (0.60–1.82)
G	C	T	C	A	G	A	0.20	0.24	0.89 (0.60–1.33)
G	C	T	C	A	G	T	0.04	0.03	1.40 (0.63–3.11)
A	C	C	C	A	G	T	0.01	0.03	0.42 (0.14–1.23)
A	C	T	C	A	G	A	0.16	0.17	0.92 (0.60–1.41)
A	T	T	C	C	G	T	<0.01	0.01	1.89 (0.64–5.59)
A	T	T	T	A	G	T	0.11	0.10	1.13 (0.70–1.81)
All rare haplotypes combined							0.54	0.51	8.63 (0.65–115)
									Score test	0.2